Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

PMID:
29431697
2.

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.

Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1.

PMID:
29196463
3.

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.

Ahronian LG, Corcoran RB.

Genome Med. 2017 Apr 21;9(1):37. doi: 10.1186/s13073-017-0431-3. Review.

4.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX.

Cancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29.

5.

Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations.

Ahronian LG, Corcoran RB.

Mol Cell Oncol. 2015 May 21;3(1):e1048405. doi: 10.1080/23723556.2015.1048405. eCollection 2016 Jan.

6.

A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination.

Ahronian LG, Zhu LJ, Chen YW, Chu HC, Klimstra DS, Lewis BC.

Oncogene. 2016 Sep 1;35(35):4653-62. doi: 10.1038/onc.2016.2. Epub 2016 Feb 15.

7.

Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.

Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB.

Cancer Discov. 2016 Feb;6(2):147-153. doi: 10.1158/2159-8290.CD-15-1283. Epub 2015 Dec 7.

8.

Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.

Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB.

Cancer Discov. 2015 Dec;5(12):1271-81. doi: 10.1158/2159-8290.CD-15-0748. Epub 2015 Oct 2. Erratum in: Cancer Discov. 2016 Dec;6(12 ):1402.

9.

The p53R172H mutant does not enhance hepatocellular carcinoma development and progression.

Ahronian LG, Driscoll DR, Klimstra DS, Lewis BC.

PLoS One. 2015 Apr 17;10(4):e0123816. doi: 10.1371/journal.pone.0123816. eCollection 2015.

10.

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM Jr, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.

Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.

11.

Using the RCAS-TVA system to model human cancer in mice.

Ahronian LG, Lewis BC.

Cold Spring Harb Protoc. 2014 Nov 3;2014(11):1128-35. doi: 10.1101/pdb.top069831.

PMID:
25368315
12.

In vivo delivery of RCAS virus to mice.

Ahronian LG, Lewis BC.

Cold Spring Harb Protoc. 2014 Nov 3;2014(11):1167-9. doi: 10.1101/pdb.prot077982.

PMID:
25368308
13.

Generation of high-titer RCAS virus from DF1 chicken fibroblasts.

Ahronian LG, Lewis BC.

Cold Spring Harb Protoc. 2014 Nov 3;2014(11):1161-6. doi: 10.1101/pdb.prot077974.

PMID:
25368307
14.

Functional activity of RLIM/Rnf12 is regulated by phosphorylation-dependent nucleocytoplasmic shuttling.

Jiao B, Taniguchi-Ishigaki N, Güngör C, Peters MA, Chen YW, Riethdorf S, Drung A, Ahronian LG, Shin J, Pagnis R, Pantel K, Tachibana T, Lewis BC, Johnsen SA, Bach I.

Mol Biol Cell. 2013 Oct;24(19):3085-96. doi: 10.1091/mbc.E13-05-0239. Epub 2013 Jul 31.

15.

KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.

Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC.

Mol Cancer Res. 2012 Sep;10(9):1228-39. Epub 2012 Aug 7.

Supplemental Content

Loading ...
Support Center